Bayesian Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Bayesian Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$527K	Buy	+13,104	New	+$282K	0.64%	50
2025 Q4	–	Sell	-25,500	Closed	-$577K	–	138
2025 Q3	$577K	Buy	+25,500	New	+$595K	0.12%	253
2025 Q2	–	Sell	-37,900	Closed	-$829K	–	537
2025 Q1	$829K	Buy	+37,900	New	+$1.05M	0.14%	206
2024 Q4	–	Sell	-31,200	Closed	-$900K	–	678
2024 Q3	$900K	Buy	+31,200	New	+$1.16M	0.11%	262
2024 Q1	–	Sell	-17,275	Closed	-$1.03M	–	770
2023 Q4	$1.03M	Buy	+17,275	New	+$876K	0.11%	228
2023 Q3	–	Sell	-9,124	Closed	-$831K	–	685
2023 Q2	$831K	Sell	9,124 -8,800	-49%	-$759K	0.09%	300
2023 Q1	$1.18M	Buy	+17,924	New	+$1.03M	0.15%	209
2022 Q3	–	Sell	-11,600	Closed	-$525K	–	687
2022 Q2	$525K	Sell	11,600 -2,400	-17%	-$109K	0.1%	322
2022 Q1	$711K	Buy	+14,000	New	+$618K	0.11%	282

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bayesian Capital Management's APLS Position: Q1 2026 in Review

Bayesian Capital Management opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 13,104 shares worth $527K. The stake represents 0.64% of the portfolio and ranks #50 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in APLS as recently as Q3 2025.

Bayesian Capital Management first reported a position in APLS in Q1 2022 and has held it in 9 quarters since. The position peaked at $1.18M in Q1 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Bayesian Capital Management held 13,104 shares of Apellis Pharmaceuticals worth $527K as of Q1 2026.
Apellis Pharmaceuticals was a new Bayesian Capital Management position in Q1 2026.
Apellis Pharmaceuticals made up 0.64% of Bayesian Capital Management's portfolio in Q1 2026, its #50 holding.
Bayesian Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
Bayesian Capital Management's Apellis Pharmaceuticals position peaked at $1.18M in Q1 2023.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Bayesian Capital Management's 13F filing for Q1 2026, filed 15 May 2026.